Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)

Cancer Investigation
M HebbarOncology Multidisciplinary Research Group (GERCOR)

Abstract

We assessed a schedule alternating 4 FOLFOX and 4 FOLFIRI cycles in 39 patients with 5-FU resistant metastatic colorectal cancer. Patients alternatively received 4 FOLFOX-6 cycles (oxaliplatin 100 mg/m(2), leucovorin 200 mg/m(2) d1 followed by bolus 400 mg/m(2) 5-FU and by a 46-hour 2,400 mg/m(2) 5-FU infusion, every 2 weeks), and 4 FOLFIRI cycles (oxaliplatin replaced by irinotecan 180 mg/m(2) d1) until progression or limiting toxicity. Eigteen patients achieved an objective response (46.1 percent). Median progression-free and overall survivals were 8.8 and 18.7 months, respectively. Only 2 patients (5.1 percent) had Grade 3 oxaliplatin-related sensory-neuropathy. This schedule had so promising efficacy and safety.

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Feb 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A de GramontM Krulik
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F Maindrault-GoebelA de Gramont
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T AndréA de Gramont
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
May 3, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M PenzW Scheithauer
May 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F Maindrault-GoebelUNKNOWN Oncology Multidisciplinary Research Group (GERCOR)
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard H WilsonJean L Grem
Jun 5, 2002·Anti-cancer Drugs·Harry Bleiberg, Alain Hendlisz
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano CascinuGiuseppina Catalano
Nov 8, 2002·Seminars in Oncology·Jim Cassidy, Jean-Louis Misset
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Apr 10, 2004·Cancer·Ada H BraunPeter Preusser
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Dec 8, 2004·Cancer Investigation·Syma IqbalHeinz-Josef Lenz
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julien TaïebAimery de Gramont

❮ Previous
Next ❯

Citations

Jun 21, 2011·International Journal of Molecular Sciences·Jérome SolassolThierry Maudelonde
Apr 7, 2010·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Han Hong LeeHae Myung Jeon
Sep 24, 2009·Journal of Pharmaceutical Sciences·Shweta R UrvaJoseph P Balthasar
Feb 19, 2008·Clinical Colorectal Cancer·David J Gallagher, Nancy Kemeny
Feb 19, 2008·Clinical Colorectal Cancer·Seth PolitanoScott Kopetz
Jul 10, 2009·International Journal of Cancer. Journal International Du Cancer·M KeeseP Bastiaens
Jul 4, 2007·Surgical Oncology Clinics of North America·Lawrence Leichman
Oct 11, 2008·American Journal of Clinical Oncology·Francesco RecchiaSilvio Rea
Feb 14, 2008·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Kathy Ruble
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Muhammad Wasif Saif, Richard Kim
Apr 25, 2012·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Robert C G MartinVivek Sharma
Jun 27, 2009·Journal of Midwifery & Women's Health·Janice TaleffEdward R Newton

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.